E
Edward Tam
Publications - 45
Citations - 1890
Edward Tam is an academic researcher. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 12, co-authored 35 publications receiving 1653 citations.
Papers
More filters
Journal ArticleDOI
ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci,David E. Bernstein,Jacob Lalezari,Daniel E. Cohen,Yan Luo,Curtis Cooper,Edward Tam,Rui Tato Marinho,Naoky Tsai,A. Nyberg,Terry Box,Ziad Younes,Pedram Enayati,Sinikka Green,Yaacov Baruch,Bal R. Bhandari,Florin Alexandru Caruntu,Thomas Sepe,Vladimir Chulanov,Ewa Janczewska,Giuliano Rizzardini,J. Gervain,Ramon Planas,Christophe Moreno,Tarek Hassanein,Wangang Xie,M. King,Thomas Podsadecki,K. Rajender Reddy +28 more
TL;DR: Twelve weeks of treatment with ABT-450/r-ombitasvir and dasabuvir without ribavirin was associated with high rates of sustained virologic response among previously untreated patients with HCV genotype 1 infection.
Journal ArticleDOI
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
Stefan Zeuzem,Graham R. Foster,Stanley Wang,Armen Asatryan,Edward Gane,Jordan J. Feld,Tarik Asselah,Marc Bourlière,Peter Ruane,Heiner Wedemeyer,Stanislas Pol,Robert Flisiak,Fred Poordad,Wan-Long Chuang,Catherine A.M. Stedman,Steven L. Flamm,Paul Y. Kwo,Gregory J. Dore,Gladys Sepulveda-Arzola,Stuart K. Roberts,Ruth Soto-Malave,Kelly Kaita,Massimo Puoti,John M. Vierling,Edward Tam,Hugo E. Vargas,Rafi Bruck,Francisco Fuster,Seung-Woon Paik,Franco Felizarta,Jens Kort,Bo Fu,Ran Liu,Teresa I. Ng,Tami Pilot-Matias,Chih-Wei Lin,Roger Trinh,Federico J. Mensa +37 more
TL;DR: Once‐daily treatment with glecaprevir–pibrentasvir for either 8 weeks or 12 weeks achieved high rates of sustained virologic response among patients with HCV genotype 1 or 3 infection who did not have cirrhosis.
Journal ArticleDOI
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
Eric Lawitz,Edward Gane,Brian L. Pearlman,Edward Tam,Wayne Ghesquiere,Dominique Guyader,Laurent Alric,Jean-Pierre Bronowicki,Laura Lester,William Sievert,Reem Ghalib,Luis A. Balart,Fredrik Sund,Martin Lagging,Frank J. Dutko,Melissa Shaughnessy,Peggy Hwang,Anita Y. M. Howe,Janice Wahl,Michael N. Robertson,Eliav Barr,Barbara Haber +21 more
TL;DR: The C-WORTHY trial as mentioned in this paper was a randomized, open-label phase 2 trial of grazoprevir plus elbasvir with or without ribavirin in patients with hepatitis C virus (HCV) genotype 1 infection with baseline characteristics of poor response.
Journal ArticleDOI
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks
Jordan J. Feld,Christophe Moreno,Roger Trinh,Edward Tam,Suzanne Bourgeois,Yves Horsmans,Magdy Elkhashab,David E. Bernstein,Ziad Younes,Robert Reindollar,Lois Larsen,Bo Fu,Kevin Howieson,Akshanth R. Polepally,Andreas Pangerl,Nancy S. Shulman,Fred Poordad +16 more
TL;DR: The HCV regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir without ribavirin for 12weeks achieved 100% SVR12 and was well tolerated in HCV genotype 1b-infected patients with cirrhosis, suggesting that this 12-week ribvirin-free regimen is sufficient in this population.
Journal ArticleDOI
Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
Fred Poordad,William Sievert,Lindsay Mollison,Michael R Bennett,Edmund Tse,Norbert Bräu,Norbert Bräu,James E. Levin,Thomas Sepe,Samuel S. Lee,Peter W Angus,Brian Conway,Stanislas Pol,Nathalie Boyer,Jean-Pierre Bronowicki,Ira M. Jacobson,Andrew J. Muir,K. Rajender Reddy,Edward Tam,Grisell Ortiz-Lasanta,Victor de Ledinghen,Mark S. Sulkowski,Navdeep Boparai,Fiona McPhee,Eric Hughes,E. Scott Swenson,Philip D. Yin +26 more
TL;DR: In this open-label, nonrandomized, uncontrolled study, a high rate of SVR12 was achieved in treatment-naive and treatment-experienced noncirrhotic patients with chronic HCV genotype 1 infection who received 12 weeks of treatment with the oral fixed-dose regimen of daclatasvir, asunaprevir, and beclabuvir.